STOCKHOLM, April 4,
2023 /PRNewswire/ -- Medivir AB (NASDAQ
Stockholm: MVIR) today announces that the Annual Report for
2022 now is available at the company's website:
www.medivir.com.
Medivir's cutting edge project fostrox has the potential to
become the first liver-targeted, orally administered drug to help
patients with various cancers of the liver, an area of great
medical need. The clinical development of fostrox has been in focus
in 2022 with a high recruitment rate in the second half of the
year, which enabled the phase 2a part of the study, with fostrox in
combination with Lenvima®, to start at the beginning of 2023.
Interest in the study remains very high.
Several of the company's out-licensed projects have developed in
a very positive direction during 2022 and are moving towards an
exciting future. For two of these projects, clinical development
programs are likely to be initiated in 2023.
This and much more can be found in Medivir's Annual Report 2022,
published today at the website;
https://www.medivir.com/investors/reports#FinancialReports2022
For additional information, please contact
Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
fostroxacitabine bralpamide (fostrox), a pro-drug designed to
selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
The following files are available for download:
|
https://mb.cision.com/Main/652/3746717/1965866.pdf
|
Annual Report 2022
(PDF)
|
|
https://mb.cision.com/Public/652/3746717/ae07d59e17436112.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivir-2022-annual-report-published-301789365.html
SOURCE Medivir
